Skip to main content
    P

    Pelthos Therapeutics Inc. (PTHS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $7.11
    -0.33 (-4.44%)

    Market Cap: $29.24M

    Last updated: Nov 17, 2026 at 11:04 AM ET

    Pelthos Therapeutics Inc. (PTHS) Earnings: Report Dates and Results

    Updated Nov 12, 2026. Results come from company earnings reports, and estimates are consensus analyst estimates.

    Pelthos Therapeutics (PTHS) is expected to report earnings on Mar 17, 2027. In the quarter ended Sep 30, 2026, Pelthos Therapeutics reported EPS of -$3.09, below the -$2.83 estimate. It beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate.

    Earnings

    Performance (10Y)

    Beat Rate
    25%(2/8)
    Avg Surprise
    -121.47%

    Upcoming Estimates

    Reports Mar 17, 2027 (est.)Period ending Dec 31, 2026
    EPS Consensus-$2.83
    Range-$4.62 - -$1.25
    9 analysts
    Revenue Consensus
    $17.53M
    Range$13.16M - $26.25M
    9 analysts

    Next Report

    PTHS has an expected report date of Mar 17, 2027.

    PTHS Earnings Call

    The latest PTHS earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    Earnings History

    Of the 8 quarters below that had an estimate, PTHS beat 2 and missed 6. Revenue for the quarter ended Sep 30, 2026 was $15.39M, up 107.7% from $7.41M a year earlier.

    Quarter endedEPSEstimateRangeSurpriseResultYoYAnalystsRevisionsReportedRevenue
    Sep 30, 2026-$3.09-$2.83-$4.60 - -$1.60-9.19%MissN/A30 up, 1 downNov 12, 2026$15.39M
    Jun 30, 2026-$6.62-$3.02-$4.19 - -$1.54-119.21%MissN/A40 up, 1 downAug 13, 2026$15.60M
    Mar 31, 2026-$4.66-$3.58-$4.49 - -$2.67-30.24%MissN/A20 up, 1 downMay 14, 2026$10.91M
    Dec 31, 2025-$2.69-$4.18N/A+35.65%BeatN/AN/AN/AMar 19, 2026$9.39M
    Sep 30, 2025-$5.30-$0.57N/A-829.82%MissN/AN/AN/ANov 13, 2025$7.41M
    Jun 30, 2025-$5.38-$6.26N/A+14.06%BeatN/AN/AN/AAug 13, 2025N/A
    Mar 31, 2025-$3.21N/AN/AN/AN/AN/AN/AN/AMay 28, 2025N/A
    Dec 31, 2024-$0.32N/AN/AN/AN/AN/AN/AN/AFeb 26, 2025N/A
    Sep 30, 2024-$2.90-$2.30N/A-26.09%MissN/AN/AN/ANov 13, 2024N/A
    Jun 30, 2024-$3.10-$2.90N/A-6.90%MissN/AN/AN/AAug 13, 2024$3527
    Mar 31, 2024-$5.50N/AN/AN/AN/AN/AN/AN/AMay 29, 2024N/A
    Last 11 quarters

    Annual EPS

    Fiscal year endedEPSChange
    Sep 30, 2026-$14.37N/A
    Jun 30, 2026-$11.28N/A
    Dec 31, 2025-$16.58N/A
    Jun 30, 2025-$19.03N/A
    Dec 31, 2024-$11.82N/A

    Earnings Calls

    The 2 most recent earnings calls are listed below; the latest, 2026Q1 for the period ended Mar 31, 2026, runs about 5,200 words across 12 speakers.

    CallPeriod endingWordsSpeakersTranscript
    2026Q1Mar 31, 20265,18612
    2025Q3Sep 30, 20256,0817

    2026Q1 Earnings Call

    Opening remarks

    Mike Moyer Host, LifeSci Advisors Good morning, everyone, and welcome to the Pelthos Therapeutics 2026 First Quarter Financial Results Conference Call. Pelthos issued a press release today announcing its financial results for the quarter ended March 31, 2026. A copy can be found in the Investor Relations tab on the corporate website, www.pelthos.com. Before we begin, I'd like to remind you that during today's call, statements about the company's future expectations, projections, plans and prospects are forward-looking statements. These forward-looking statements are based on management's current expectations. These statements are neither promises nor guarantees and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from our current expectations expressed or implied by the forward-looking statements. Any such forward-looking statements represent management's estimates as of the date of this conference call. While the company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so even if subsequent events cause its views to change. As a reminder, this conference call is being recorded and will remain available for 90 days. I'd now like to turn the floor over to Scott Plesha, Chief Executive Officer. Sir, you may begin.

    Scott Plesha Chief Executive Officer Thank you, Mike, and good morning, everyone. We're delighted to be with you today to share with you our first quarter 2026 operating results and highlights. Joining me today are John Gay, our Chief Financial Officer; and Sai Rangarao, our Chief Commercial Officer. The first quarter of 2026 was a successful one for Pelthos, with strong execution and progress made in several key areas that I'll share at a high level with you. First, we experienced substantial revenue growth driven by increased prescriptions of our lead product, ZELSUVMI during its third quarter since its launch. Next we completed the expansion and optimization of our sales force from 50 sales representatives to 64. We believe that the expansion of our sales force and the contracts we executed with a major pharmacy benefit manager in December 2025, have been important catalysts in demand for ZELSUVMI since January. Within this PBM, units dispensed have doubled and the number of prescribers has increased 121%. Finally, we continue to make progress in establishing the manufacturing of our two other highly complementary products, XEPI and XEGLYZE. John and Sai will provide a more detailed look at the quarter's ZELSUVMI launch metrics and reported financial results, but I'd like to share a brief overview of our results of operations.

    Frequently Asked Questions About PTHS

    When is Pelthos Therapeutics's next earnings date?

    Pelthos Therapeutics's next earnings report is expected for Mar 17, 2027.

    Did PTHS beat earnings estimates last quarter?

    No. Pelthos Therapeutics reported EPS of -$3.09 for the quarter ended Sep 30, 2026, below the -$2.83 estimate by 9.19%.

    What EPS do analysts expect from PTHS next quarter?

    The consensus EPS estimate for Pelthos Therapeutics for the quarter ending Dec 31, 2026 is -$2.83 from 9 analysts, with estimates from -$4.62 to -$1.25.

    How often does PTHS beat earnings estimates?

    Pelthos Therapeutics beat the EPS estimate in 2 of the 8 most recent quarters that had an estimate, with an average surprise of -121.47%.